SARAH HADEN VANCE: Open Payments
NPI 1609474725 · HOOVER, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,811 in 86 payments from 12 companies in 2025. Trend: 2023 $1,166 · 2024 $907 · 2025 $1,811
Food & beverage: $1,811
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 14 | $306 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $301 |
| Axsome Therapeutics, Inc. | 10 | $247 |
| ABBVIE INC. | 19 | $222 |
| Vanda Pharmaceuticals Inc. | 6 | $190 |
| Teva Pharmaceuticals USA, Inc. | 8 | $154 |
| Lundbeck LLC | 4 | $114 |
| Neurocrine BioSciences, Inc. | 3 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| Janssen Pharmaceuticals, Inc | 3 | $55 |
Products named: CAPLYTA, REXULTI, Auvelity, VRAYLAR, FANAPT, ABILIFY MAINTENA, UZEDY, INGREZZA.
Industry payments across AL — which companies pay providers there.
